

Aideen E Ryan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5187166/publications.pdf>

Version: 2024-02-01

69
papers

3,124
citations

201385

27
h-index

189595

50
g-index

72
all docs

72
docs citations

72
times ranked

5504
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. <i>Gut</i> , 2022, 71, 2502-2517.	6.1	4
2	Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. <i>Oncolmmunology</i> , 2021, 10, 1859263.	2.1	13
3	A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance. <i>Cancers</i> , 2021, 13, 227.	1.7	48
4	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
5	Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in mice. <i>Stem Cell Research and Therapy</i> , 2021, 12, 227.	2.4	7
6	Nitric Oxide Modulates Metabolic Processes in the Tumor Immune Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7068.	1.8	21
7	Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer. <i>Cancers</i> , 2021, 13, 5998.	1.7	8
8	Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. <i>Blood</i> , 2021, 138, 2756-2756.	0.6	1
9	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17808-17819.	3.3	18
10	TGF- β 1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo. <i>Molecular Therapy</i> , 2020, 28, 2023-2043.	3.7	38
11	Administration of Human Non-Diabetic Mesenchymal Stromal Cells to a Murine Model of Diabetic Fracture Repair: A Pilot Study. <i>Cells</i> , 2020, 9, 1394.	1.8	4
12	Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e350.	1.2	29
13	Abstract 3867: STAT1-related antigen processing and presentation dictates prognosis in the fibroblast-rich subtype of stage II/III colon cancer. , 2020, , .		3
14	Abstract 2409: FLIP(L) determines colon cancer cell fate following p53 activation. , 2020, , .		0
15	865â€¦Sugar high: Does the sialic acid profile of cancer-associated fibroblasts induce a more tumour-permissive microenvironment?. , 2020, , .		0
16	864â€¦The mesenchymal stromal compartment in colorectal cancer greatly alters the innate tumour immune microenvironment both in 2D and 3D culture systems. , 2020, , .		0
17	TNF- α /IL-1 β -licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3 ⁺ regulatory T cells in the lung. <i>FASEB Journal</i> , 2019, 33, 9404-9421.	0.2	37
18	CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. <i>Blood Advances</i> , 2019, 3, 1815-1825.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Mesenchymal Stromal Cell Sialylation Modulates Antitumor Immune Responses In Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e93-e94.	0.2	1
20	Mesenchymal stem cell therapy for osteoarthritis: how apoptotic cells modulate inflammation. <i>Osteoarthritis and Cartilage</i> , 2018, 26, S297.	0.6	3
21	Extracellular vesicles as modulators of wound healing. <i>Advanced Drug Delivery Reviews</i> , 2018, 129, 394-406.	6.6	116
22	Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumorigenic "activated" state that enhances prostate cancer cell migration. <i>International Journal of Cancer</i> , 2018, 142, 2056-2067.	2.3	27
23	Interspecies Incompatibilities Limit the Immunomodulatory Effect of Human Mesenchymal Stromal Cells in the Rat. <i>Stem Cells</i> , 2018, 36, 1210-1215.	1.4	21
24	Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 2666.	2.2	39
25	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1426-1441.	1.6	66
26	Establishment of the in vivo immunological profile in collagenase induced osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2018, 26, S127.	0.6	0
27	Abstract 3789: Role of NOS2-COX2 crosstalk in tumor microenvironment of estrogen receptor-negative breast cancer and its therapeutic implications. , 2018, , .		0
28	Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13030-13035.	3.3	81
29	Inducible Expression of Viral Interleukin 10 in Mouse Mesenchymal Stem Cells Increases their Immuno-suppressive Capacity. <i>Osteoarthritis and Cartilage</i> , 2017, 25, S267.	0.6	0
30	Regulating Immunogenicity and Tolerogenicity of Bone Marrow-Derived Dendritic Cells through Modulation of Cell Surface Glycosylation by Dexamethasone Treatment. <i>Frontiers in Immunology</i> , 2017, 8, 1427.	2.2	10
31	Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?. <i>Frontiers in Immunology</i> , 2017, 8, 1626.	2.2	116
32	Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. <i>Oncotarget</i> , 2017, 8, 80568-80588.	0.8	61
33	Abstract 2693: Inflammatory signalling in the colon tumour microenvironment enhances stromal cell mediated suppression of anti-tumour immune responses. , 2017, , .		0
34	vIL-10-overexpressing human MSCs modulate naïve and activated T lymphocytes following induction of collagenase-induced osteoarthritis. <i>Stem Cell Research and Therapy</i> , 2016, 7, 74.	2.4	25
35	Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes. <i>Equine Veterinary Journal</i> , 2016, 48, 253-260.	0.9	28
36	Culture expanded primary chondrocytes have potent immunomodulatory properties and do not induce an allogeneic immune response. <i>Osteoarthritis and Cartilage</i> , 2016, 24, 521-533.	0.6	23

#	ARTICLE	IF	CITATIONS
37	Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. <i>Oncogene</i> , 2016, 35, 1261-1270.	2.6	54
38	Potential of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP. <i>Blood</i> , 2016, 128, 2101-2101.	0.6	13
39	Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?. <i>Oncotarget</i> , 2016, 7, 60752-60774.	0.8	56
40	Immune Modulation to Improve Tissue Engineering Outcomes for Cartilage Repair in the Osteoarthritic Joint. <i>Tissue Engineering - Part B: Reviews</i> , 2015, 21, 55-66.	2.5	50
41	Mechanisms of Nitric Oxide-Dependent Regulation of Tumor Invasion and Metastasis. , 2015, , 49-63.		1
42	Allogeneic chondroprogenitors display immunosuppressive properties and are non-immunogenic in vitro. <i>Osteoarthritis and Cartilage</i> , 2015, 23, A267.	0.6	0
43	Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. <i>Molecular Therapy</i> , 2015, 23, 812-823.	3.7	877
44	Pullulan: a new cytoadhesive for cell-mediated cartilage repair. <i>Stem Cell Research and Therapy</i> , 2015, 6, 34.	2.4	38
45	Targeting colon cancer cell NF- κ B promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis. <i>Oncogene</i> , 2015, 34, 1563-1574.	2.6	47
46	Chondrogenic Differentiation Increases Antidonor Immune Response to Allogeneic Mesenchymal Stem Cell Transplantation. <i>Molecular Therapy</i> , 2014, 22, 655-667.	3.7	76
47	Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?. <i>Stem Cell Research and Therapy</i> , 2014, 5, 99.	2.4	61
48	Mesenchymal Stem Cell Therapy Promotes Corneal Allograft Survival in Rats by Local and Systemic Immunomodulation. <i>American Journal of Transplantation</i> , 2014, 14, 2023-2036.	2.6	42
49	Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an <i>in vivo</i> model of colon cancer. <i>International Journal of Cancer</i> , 2013, 133, 825-834.	2.3	21
50	Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. <i>Immunology and Cell Biology</i> , 2013, 91, 40-51.	1.0	205
51	Donor Bone Marrow-derived Dendritic Cells Prolong Corneal Allograft Survival and Promote an Intra-graft Immunoregulatory Milieu. <i>Molecular Therapy</i> , 2013, 21, 2102-2112.	3.7	13
52	Effects of Intratracheal Mesenchymal Stromal Cell Therapy during Recovery and Resolution after Ventilator-induced Lung Injury. <i>Anesthesiology</i> , 2013, 118, 924-932.	1.3	92
53	Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. <i>Thorax</i> , 2012, 67, 496-501.	2.7	238
54	Mo1615 Targeting FasL Increases the Anti-Tumor Immune Response in an In Vivo Model of Colon Cancer.. <i>Gastroenterology</i> , 2012, 142, S-642.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Adenoviral Transduction of Mesenchymal Stem Cells: In Vitro Responses and In Vivo Immune Responses after Cell Transplantation. PLoS ONE, 2012, 7, e42662.	1.1	31
56	Autophagosomal I κ B α Degradation Plays a Role in the Long Term Control of Tumor Necrosis Factor- α -induced Nuclear Factor- κ B (NF- κ B) Activity. Journal of Biological Chemistry, 2011, 286, 22886-22893.	1.6	57
57	Regulation of NF- κ B responses by epigenetic suppression of I κ B α expression in HCT116 intestinal epithelial cells. American Journal of Physiology - Renal Physiology, 2010, 299, G96-G105.	1.6	24
58	M1808 Analysis of the IL-6/STAT3/AKT Signalling Pathways in Patients With Inflammatory Bowel Disease: Effect of Disease Activity and Duration. Gastroenterology, 2010, 138, S-423.	0.6	0
59	557 TNF- α -Induced Long-Term NF- κ B Activation in Intestinal Epithelial Cells: Evidence for Autophagic Degradation of I κ B α . Gastroenterology, 2010, 138, S-77.	0.6	0
60	W1761 Inhibition of NF- κ B in Colon Cancer Cells Prevents Peritoneal Dissemination Through Polarisation of Tumor-Associated Macrophages Towards an M1-Like Phenotype. Gastroenterology, 2010, 138, S-734.	0.6	0
61	T1993 Inhibition of NF- κ B in Colon Cancer Cells Significantly Decreases Tumour Burden and Increases Survival Time in a Mouse Model of Peritoneal Metastasis. Gastroenterology, 2009, 136, A-616.	0.6	0
62	The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Human Pathology, 2008, 39, 243-250.	1.1	21
63	Fas Ligand Promotes Tumor Immune Evasion of Colon Cancer In Vivo. Cell Cycle, 2006, 5, 246-249.	1.3	38
64	Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. Journal of Carcinogenesis, 2006, 5, 5.	2.5	16
65	Induction of Apoptosis in Renal Cell Carcinoma by Reactive Oxygen Species: Involvement of Extracellular Signal-Regulated Kinase 1/2, p38 β / δ , Cyclooxygenase-2 Down-Regulation, and Translocation of Apoptosis-Inducing Factor. Molecular Pharmacology, 2006, 69, 1879-1890.	1.0	28
66	Addressing the "Fas Counterattack" Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer In vivo. Cancer Research, 2005, 65, 9817-9823.	0.4	83
67	Rapid Development of a Quantitative-Competitive (qc) RT-PCR Assay Using a Composite Primer Approach. , 2002, 193, 093-102.		2
68	Local administration of non-diabetic MSCs to diabetic femoral fractures enhances callus remodelling and deposition of reparative bone. Endocrine Abstracts, 0, , .	0.0	0
69	AB066. Elucidating the circulating and tumour-specific immune populations in a cohort of colon cancer patients. Mesentery and Peritoneum, 0, 4, AB066-AB066.	0.1	0